Argenx Stock - H.C. Wainwright reiterates Buy rating and $940 target

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 13:28 CET. Details in the imprint.

Argenx (NL0010832176) stays on the radar of Wall Street analysts. H.C. Wainwright has reiterated its Buy rating on the stock and confirmed a $940 price target, according to a recent analyst update.

What H.C. Wainwright says

According to a recent note cited by German financial portal Finanzen100, H.C. Wainwright reaffirmed its Buy stance on Argenx shares and maintained a $940 price target, underscoring continued confidence in the company’s immunology pipeline.

The reiteration follows a stretch in which Argenx has become one of the higher-valued European biotech names, with a market capitalization around $55 billion on its Nasdaq listing.

Analyst sentiment and valuation

Overall analyst sentiment on Argenx remains constructive. Data compiled by TradingKey show the stock carries a consensus rating of Buy with an average price target near $1,045.49, indicating that H.C. Wainwright’s $940 target is slightly below the broader mean.

Institutional ownership also remains robust. TradingKey points to institutional investors holding more than half of the shares, at roughly 50.86%, even after a quarter-on-quarter decrease in that proportion.

Long-term growth story in focus

Argenx positions itself as a long-term growth company in autoimmune diseases, building a portfolio of antibody-based therapies beyond its first commercial product. Management stresses continued investment in research and development to expand indications and secure durable revenue streams.

For long-horizon investors, the key question is whether Argenx can translate its scientific platform into a sequence of successful launches that justify both current valuation and ambitious analyst targets.

How the company makes money

Argenx generates revenue primarily from efgartigimod-based therapies for autoimmune conditions, including generalized myasthenia gravis, while also collecting milestone and collaboration income from partnered programs. The broader pipeline targets additional neuromuscular and hematologic diseases to diversify future cash flows.

Where the stock trades today

Argenx shares (NL0010832176) last traded on Nasdaq at $877.72 as of 06/18/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.